Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Cancer Epidemiol Biomarkers Prev. 2023 Apr 3;32(4):531-541. doi: 10.1158/1055-9965.EPI-22-1134.
Previous studies indicated that glucosamine supplements may have a general anticancer effect. This study aimed to assess whether the potential effect differs across different types of cancers in a large prospective cohort study.
All participants from the UK Biobank who were free of cancers and had complete information on glucosamine use at baseline were included and followed up from 2006 until 2021. Cox proportional hazards models were used to assess the associations between regular glucosamine use and different site-specific cancers. Subgroup analyses were performed to explore potential interactions. Several sensitivity analyses were conducted to assess the robustness of the main findings.
A total of 450,207 eligible participants (mean age: 56.2 years; females: 53.3%) were included, of whom 84,895 (18.9%) reported regular glucosamine use at baseline. During a median of 12.5 years follow-up, glucosamine use was significantly associated with an increased risk of overall cancer [HR, 1.04; 95% confidence interval (CI), 1.01-1.06], skin cancer (HR, 1.11; 95% CI, 1.07-1.15), and prostate cancer (HR, 1.07; 95% CI, 1.01-1.13), and with a reduced risk of lung cancer (HR, 0.88; 95% CI, 0.79-0.97) after adjusting for potential confounders. Statistical interaction was observed for gender, age, and education for the association of glucosamine use with overall cancer risk (all Pinteraction < 0.027). These results remained unchanged in the sensitivity analyses.
Regular glucosamine use was associated with lower risk of lung cancer but higher risk of skin cancer, prostate cancer, and overall cancer.
The roles of glucosamine use potentially differ in the development of different site-specific cancers.
先前的研究表明，氨基葡萄糖补充剂可能具有普遍的抗癌作用。本研究旨在通过一项大型前瞻性队列研究评估其在不同类型癌症中的潜在作用是否存在差异。
纳入所有来自英国生物银行的无癌症且在基线时完整报告氨基葡萄糖使用情况的参与者，并从 2006 年随访至 2021 年。采用 Cox 比例风险模型评估常规使用氨基葡萄糖与不同部位特异性癌症之间的关联。进行亚组分析以探索潜在的交互作用。进行了几项敏感性分析，以评估主要发现的稳健性。
共纳入 450,207 名符合条件的参与者（平均年龄：56.2 岁；女性：53.3%），其中 84,895 名（18.9%）基线时报告常规使用氨基葡萄糖。在中位数为 12.5 年的随访期间，使用氨基葡萄糖与总体癌症风险增加显著相关[风险比（HR），1.04；95%置信区间（CI），1.01-1.06]、皮肤癌（HR，1.11；95%CI，1.07-1.15）和前列腺癌（HR，1.07；95%CI，1.01-1.13），而肺癌风险降低（HR，0.88；95%CI，0.79-0.97），调整了潜在混杂因素后。性别、年龄和教育对氨基葡萄糖使用与总体癌症风险之间关联的统计学交互作用存在（所有 P 交互值均<0.027）。这些结果在敏感性分析中保持不变。
常规使用氨基葡萄糖与肺癌风险降低相关，但与皮肤癌、前列腺癌和总体癌症风险增加相关。
氨基葡萄糖的使用作用在不同部位特异性癌症的发展中可能存在差异。
